Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: A single-center retrospective analysis - 19/08/20
, D. Gezer a , T.H. Brummendorf a , M. Crysandt a, 1, ⁎ , S. Wilop a, b, 1 Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 6 |
| Iconografías | 0 |
| Vídeos | 0 |
| Otros | 0 |
Abstract |
Purpose of the study |
In the past years, high dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT)has more extensively been performed in elderly patients with multiple myeloma (MM). Several studies found a similar survival benefit compared to younger patients. The objective of our retrospective study is to analyse the tolerability of HDT + ASCT in elderly patients.
Patients and methods |
We compared 26 ASCT performed in MM patients ≥65 years to 127 ASCT in patients <65 years by evaluating treatment-tolerability, length of hospital stay and number of transfusions.
Results |
There was no significant difference in the duration of hospitalisation (16 days (range 14–47) in the elderly vs. 17 days (range 14–71) days, P = 0.0903), median time of cytopenia (neutrophils<500/μl: 5 days (range 4–24) vs. 6 days (range 3–28) days, P = 0.1091; platelets<30 000/μl: 6 days (range 3–36) vs. 7 days (range 0–53) days, P = 0.274) or incidence of, or degree of complications between the two age-groups. Immediate and day 100 treatment related mortality (TRM) was comparable in both groups (3.85% vs. 1.58%, P = 0.4304).
Conclusion |
our findings support the concept that HDT + ASCT can be safely administered as first-line option for well-selected patients≥65 years.
El texto completo de este artículo está disponible en PDF.Keywords : Multiple myeloma, Elderly patients, Autologous stem cell transplantation, High-dose melphalan
Esquema
Vol 68 - N° 3
P. 139-144 - août 2020 Regresar al número
Artículo precedente
- Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status
- Moussab Damlaj, Farhan Khalid, Bader Alahmari, Ahmed Alaskar, Samer Ghazi, Sameera Johani, Abdulrahman AlSaedy, Mohammad Bosaeed, Ayman Alhejazi, Mohsen Al-Zahrani
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?